Xenon and nitrous oxide do not depress cardiac function in an isolated rat heart model

[Le xénon et le protoxyde d'azote ne diminuent pas la fonction cardiaque d'un cœur de rat isolé]

Harumi Nakayama MD,* Hiroshi Takahashi MD,† Naomitsu Okubo MD,† Masayuki Miyabe MD,† Hidenori Toyooka MD†

Purpose: To examine the inotropic and chronotropic effects of xenon (Xe) and nitrous oxide (N_2O) compared with nitrogen (N_2) on isolated rat hearts. The differences between Xe and N_2O were also compared.

Methods: The effects of Xe, N₂O and N₂ on coronary perfusion pressure (CPP), heart rate, left ventricular developed pressure (LVDP) and double product (DP) were examined in isolated rat hearts perfused at constant flow (10 mL·min⁻¹). Following stabilization and baseline measurement with 95% O₂ (plus 5% CO₂), the heart was exposed to buffer equilibrated with one of three test gases; 50% N₂ with 45% O₂ (Group N₂: n=9), 50% Xe with 45% O₂ (Group Xe: n=9), or 50% N₂O with 45% O₂ (Group N₂O: n=9) for 30 min. Measurements were performed in the last minute of exposure to the test gases.

Results: Gas exposure in all three groups decreased O_2 delivery (-50%), CPP (-11%), LVDP (-30%) and DP (-44%) compared with baseline values (P < 0.001). However, there were no differences among the groups.

Conclusion: Our data suggest that cardiac contractility was decreased by the effects of reduced O_2 delivery, but both Xe and N_2O did not cause further cardiac depressant effects compared to N_2 in this experimental model.

Objectif: Vérifier les effets inotropiques et chronotropiques du xénon (Xe) et du protoxyde d'azote (N_2O) comparés à ceux de l'azote (N_2) sur des cœurs de rats isolés. Comparer aussi les différences entre le Xe et le N_2O .

Méthode : Les effets du Xe, de N_2O et de N_2 sur la pression de perfusion coronarienne (PPC), la fréquence cardiaque (FC) la pression développée dans le ventricule gauche (PDVG) et le double produit (DP) ont été vérifiés dans des cœurs de rat isolés perfusés à débit constant (10 mL·min⁻¹). Après la stabilisation et les mesures de base avec de l'O₂ à 95 % (plus du CO₂ à 5 %), le cœur a été exposé à un tampon équilibré avec l'un des trois gaz expérimentaux ; N₂ à 50 % avec O₂ à 45 % (Groupe N₂ : n = 9), Xe à 50 % avec O₂ à 45 % (Groupe Xe : n = 9) ou N₂O à 50 % avec O₂ à 45 % (Groupe N₂O : n = 9) pendant 30 min. Les mesures ont été faites pendant la dernière minute de l'exposition aux gaz testés.

Résultats : Dans les trois groupes, l'exposition aux gaz a réduit l'apport d'O₂ (-50 %), la PPC (-11 %), la PDVG (-30 %) et le DP (-44 %) par rapport aux mesures initiales (P < 0,001). Il n'y a cependant pas eu de différence intergroupe.

Conclusion : Nos données laissent croire que la contractilité cardiaque a été abaissée par les effets d'un apport réduit d' $O_{2^{1}}$ mais que ni le Xe ni le N_2O comparés au N_2 n'ont causé de dépression cardiaque supplémentaire chez ce modèle expérimental.

ENON (Xe) has many of the properties of an ideal anesthetic, because it is non-explosive, non-toxic, non-teratogenic, and probably is not metabolized.^{1–3} Xe also offers rapid induction and recovery from anesthesia^{4,5} due to its extremely low blood/gas partition coefficient (0.115–0.14).^{6,7} The minimum alveolar concentration (MAC) of Xe is 71% in humans, indicating that it is a moderately more potent anesthetic than nitrous oxide (N₂O) (104%).^{6,8} In these respects, Xe has been proposed as a replacement for N₂O in clinical use.^{4,9} However, the direct and global effects of Xe on the heart have not been compared with those of N₂O.

From the Department of Anesthesia,* Ushiku Aiwa General Hospital, and the Department of Anesthesiology,† Institute of Clinical Medicine, University of Tsukuba, Ibaraki, Japan.

Address correspondence to: Dr. Harumi Nakayama, Department of Anesthesia, Ushiku Aiwa General Hospital, 896 Shishiko-cho,

Ushiku-shi, Ibaraki 300-1296, Japan. Phone: 011-81-298-73-3111; Fax: 011-81-298-74-1031; E-mail: hami@sky.zero.ad.jp

Supported by a Grants-in-Aid for Scientific Research No. 10770740 from the Ministry of Education, Science and Culture, Tokyo Japan. Accepted for publication August 15, 2001.

Revision accepted September 17, 2001.

The current investigation examined the action of Xe compared with N_2O and nitrogen (N_2) in isolated rat hearts using the Langendorff preparation to avoid the mechanical, humoral and autonomic nervous system influences of Xe.

We tested the hypothesis that 50% Xe does not produce inotropic or chronotropic adverse effects compared with the effects of N_2O on isolated rat hearts.

Materials and methods

Langendorff heart preparation

The study protocol was approved by the Institutional Animal Care Committee of the University of Tsukuba. Twenty seven male Sprague-Dawley rats (weighing 380-460 g, aged 13-14 weeks) were injected ip with 35 mg (76-92 mg·kg⁻¹) sodium pentobarbitone and 1,000 units heparin. Following thoracotomy, the heart was rapidly excised and perfused via retrograde cannulation of the aorta in a Langendorff apparatus at a constant flow of 10 mL·min⁻¹ (Radnoti Grass®; Monrovia, CA, USA) using modified Krebs-Henseleit (K-H) buffer.¹⁰ K-H buffer was composed of (mM) NaCl 118, KCl 4.7, KH₂PO 1.2, MgSO₄ 1.2, CaCl₂ 2.8, NaHCO₃ 25, glucose 5.5 and sodium pyruvate 2.0. Constant flow was maintained throughout the experiment. Buffer and bath temperatures were maintained at $37.5 \pm 0.3^{\circ}$ C throughout the experiment with a thermostatically controlled recirculating water bath (Harvard Thermocirculator®, Kent, UK).

Systolic left ventricular pressure was measured isovolumetrically with a transducer connected to a thin, salinefilled, latex balloon. The balloon was inserted into the left ventricle through the mitral valve via an incision in the left atrium. Balloon volume was adjusted to create an end-diastolic left ventricular pressure of 0 or less than 5 mmHg during the initial baseline period. The volume of the balloon was not modified until the end of the experiment. Spontaneous heart rate (HR) was determined from the left ventricular contraction interval. Left ventricular developed pressure (LVDP) was calculated by subtracting end-diastolic left ventricular pressure from left ventricular peak systolic pressure, which was regarded as an index of contractile function of the isolated heart. Double product (DP) was calculated as follows: HR \times LVDP/1000, which is an estimate of myocardial oxygen demand. Coronary perfusion pressure (CPP), which reflects coronary artery resistance, was measured by a pressure transducer (TruWave[™] UK0804SA, Edwards, Inc., CA, USA) connected to the aortic cannula, the tip of which was positioned just above the aortic valve. Isovolumetric left ventricular pressure, spontaneous HR and CPP were measured continuously (M1166A Model 66S, Hewlett Packard Co. Ltd., Boeblingen, Germany). Oxygen delivery (DO₂) was calculated from the inflow O_2 tension $\times O_2$ solubility $(0.0031 \text{ mL} \cdot \text{mmHg}^{-1} \cdot 100 \text{ mL}^{-1}) \times \text{coronary flow per}$ gram wet heart tissue.¹¹ Oxygen extraction ratio was calculated as follows: (inflow O2 content - outflow O2 content) \times 100 / inflow O₂ content.

Protocol

Before the experiment, four cylinders containing 95% $O_2 + 5\% CO_2$, 50% $N_2 + 45\% O_2 + 5\% CO_2$, 50% Xe + 45% $O_2 + 5\% CO_2$, and 50% $N_2O + 45\% O_2 + 5\% CO_2$

	Group N_2 (n=9)		Group Xe (n=9)		Group $N_2O(n=9)$	
	95% O ₂	$50\% N_2$	95% O ₂	50% xenon	$95\% \ O_2$	50% nitrous oxide
pН	7.44 ± 0.02	7.45 ± 0.03	7.44 ± 0.02	7.45 ± 0.02	7.43 ± 0.03	7.44 ± 0.03
PCO ₂ (mmHg)	34 ± 3	33 ± 2	34 ± 2	33 ± 1	33 ± 3	32 ± 3
PO ₂ (mmHg)	573 ± 11	$285 \pm 8*$	577 ± 7	288 ± 11*	591 ± 12	297 ±9*
$DO_2 (\mu L \cdot g^{-1} \cdot min^{-1})$	131 ± 4	$65 \pm 2*$	130 ± 4	$66 \pm 2*$	131 ± 6	$66 \pm 3*$

TABLE I Inflow pH, PCO₂, PO₂ and calculated DO₂

Data are mean \pm SEM. DO₂=oxygen delivery; PCO₂=carbon dioxide tension; PO₂=oxygen tension. **P* < 0.05 *vs* baseline (95% O₂).

	Group N_2 (n=9)		Group Xe (n=9)		Group N_2O (n=9)	
	95% O ₂	50% N ₂	95% O ₂	50% xenon	95% O ₂	50% nitrous oxide
CPP (mmHg)	44 ± 1	38 ± 1*	46 ± 1	40 ± 1*	42 ± 1	38 ± 2*
HR (beats.min ⁻¹)	249 ± 4	223 ± 9	252 ± 6	215 ± 9	248 ± 7	224 ± 12
LVDP (mmHg)	102 ± 3	70 ± 3*	98 ± 3	$66 \pm 3*$	108 ± 5	$73 \pm 4*$
DP (mmHg x 1000·min ⁻¹)	25 ± 1	$15 \pm 1*$	25 ± 1	$14 \pm 1*$	27 ± 1	$16 \pm 1*$

Data are mean \pm SEM. CPP=coronary perfusion pressure; HR=heart rate; LVDP=left ventricular developed pressure; DP=double product. $*P < 0.05 \ vs$ baseline (95% O₂).




FIGURE Percent change of cardiac variables from baseline. There were no differences in % change of cardiac variables between groups N₂, Xe and N₂O. CPP=coronary perfusion pressure; HR=heart rate; LVDP=left ventricular developed pressure; DP=double product. *P <0.05 vs baseline.

were prepared. The concentration of each gas in the cylinders was measured by gas chromatography. After 30 min of perfusion with buffer for equilibration with 95% O_2 and 5% CO_2 , baseline measurements were taken. The hearts were then randomly assigned to one of three groups. In Group N₂ (*n*=9), the hearts were exposed to buffer equilibrated with 50% N₂, 45% O₂ and 5% CO₂. In Group Xe (*n*=9), the hearts were exposed to buffer equilibrated with 50% Xe, 45% O₂ and 5% CO₂. In Group N₂O (*n*=9), the hearts were exposed to buffer equilibrated with 50% Xe, 45% O₂ and 5% CO₂. In Group N₂O (*n*=9), the hearts were exposed to buffer equilibrated with 50% N₂O, 45% O₂ and 5% CO₂. After a 30-min period of exposure to buffer with test gases, measurements were made.

Statistics

All data are expressed as mean \pm SEM. Statistical analysis was performed on a personal computer with the statistical package SPSS® for Windows (available software package SPSS® for Windows 9.0.1 J). Variables were analyzed twice: by paired t test to analyze change from baseline, and by ANOVA to analyze between group differences. *P* values of less than 0.05 were considered significant.

Results

Inflow pH and carbon dioxide tension (PCO_2) were identical in the three groups. Oxygen tension (PO_2) and calculated DO_2 decreased in the three groups after exposure to buffer equilibrated with test gases. However, there were no statistically significant differences among the three groups (Table I). CPP, LVDP and DP were decreased by exposure to buffer equilibrated with test gases. However, these variables were not different among the three groups (Table II).

Percent changes of CPP, LVDP and DP from baseline decreased in all three groups. However, these changes were not different among the groups (Figure).

Oxygen extraction ratio decreased significantly (P < 0.001) with exposure to Xe (-28 ± 6%), N₂O (-25 ± 2%) and N₂ (-27 ± 4%) compared with 95% O₂. However, there were no differences between the three groups.

Discussion

In the present study, the administration of Xe, as well as N_2O , produced cardiodepressant effects in isolated rat hearts; however, these were identical to the effects of N_2 . This means that the cardiodepressant effects observed with Xe and N_2O were due to reduced oxygen delivery, and that Xe or N_2O themselves did not have cardiodepressant effects.

Previously, many studies have surmised that Xe causes minimal cardiovascular effects. Xe produced little effects on hemodynamics in pigs,12 and minimal cardiovascular effects were observed in dogs with and without experimental dilated cardiomyopathy during Xe inhalation.¹³ The latter finding indirectly suggested that Xe may be tolerated in unfavourable conditions, i.e., preexisting LV dysfunction. Xe has been shown not to alter voltage-gated ion channels in the myocardium,¹⁴ nor does it sensitize the myocardium to the dysrhythmogenic effects of epinephrine.¹⁵ In humans, Xe was also found to provide stable cardiovascular conditions.^{2,5,16} Stowe et al. reported that Xe displayed no, or very minimal, physiologically important effects on isolated erythrocyte-perfused guinea pig hearts.¹⁷ Our results are consistent with these findings in that, regarding cardiac depressant effects, Xe exhibited no difference relative to N_2 in isolated rat hearts.

Several studies have suggested that Xe might cause a decrease in HR,^{3,16,18,19} despite reports of little effect on hemodynamics in *in vivo* studies. The current investigation examined the effects of Xe in isolated rat hearts with Langendorff perfusion to avoid mechanical, humoral, and autonomic nervous system influences of the gas. Our results show that isolated hearts maintained a stable spontaneous HR during exposure to Xe. Xe was reported to depress both sympathetic and parasympathetic transmission more than isoflurane at 0.8 MAC, and was suggested to be relatively vagotonic in clinical trials.²⁰ Further, the HR response can vary with autonomic tone and baroreflex activation.²¹ Therefore, the decrease in HR with Xe *in vivo* may be

mediated *via* the cardiac autonomic nervous system. Xe is also capable of preventing activation of the adrenal medullary system³ and inhibits adrenal secretion,^{3,12} which might result in decreased HR *in vivo*.

Many years of clinical experience with N₂O indicate that it possesses mild cardiovascular depressant effects that may be counterbalanced by a simultaneous, reflexly mediated increase in sympathetic tone. These studies demonstrated small increases,22 small decreases,²³ or no change²⁴ in indices of contractility. A few in vitro investigations regarding the effects of N2O on myocardial muscle have indicated that N₂O depressed contractility similar to, or more than that in controls.²⁵⁻²⁷ Regarding sympathetic effects, N₂O, but not Xe, has been reported to augment its outflow. The sympathetic activation by N₂O has been shown by elevated plasma catecholamine concentrations²³ and by microneurography.^{28,29} This sympatho-activating property of N₂O can complicate evaluation of its cardiovascular effects and direct effects on cardiac function. In an isolated global heart study, Stowe et al. reported that N2O caused only small but significant depression of indices of cardiac contractility.¹¹ Our findings, however, showed that 50% N₂O produced no cardiodepressant effects compared with an identical concentration of N2, which is inconsistent with their report.¹¹ No statistically significant difference between Xe, N₂O and N₂ could be shown but N₂O tended to be cardiodepressant. The number of hearts studied in the current laboratory investigation may not have been sufficient to confirm the cardiodepressant effects of N2O. Meanwhile, Xe did not depress cardiac function more than N2O, at least in the absence of autonomic influence or changes in preload and afterload.

The effect of the restriction of O_2 delivery is a limitation of the current investigation. The hearts were solely dependent on the crystalloid solution from which to extract dissolved O_2 . Exposure to 50% Xe (i.e., exposure to 45% O_2) decreased O_2 delivery with, possibly, a consequent mild hypoxic condition in isolated hearts¹¹ (Table I). Even under such conditions, however, Xe produced identical changes in CPP, LVDP and DP compared with N₂.

As mentioned initially, Xe surpasses N_2O in several points; lower blood/gas partition coefficient (0.115–0.14),^{6,7} higher MAC (71% in humans),^{6,8} and innocuousness to the environment, because Xe is prepared by fractional distillation of atmospheric air. Therefore, the replacement of N_2O with Xe may become appropriate when delivery systems (i.e., closed circuit) become available with efficient techniques for recycling the gas to decrease the cost of Xe anesthesia.³⁰

In conclusion, 50% Xe produced cardiac effects identical to those of N_2O or N_2 in isolated rat hearts under conditions of decreased O_2 delivery. Xe itself lacks cardiodepressant effects and may become a useful alternative to N_2O .

Acknowledgements

The authors wish to thank Air Water Inc. for their generous donation of Xe. The authors also thank Ms. Yumi Isaka and Mr. Yasuyuki Baba for their technical assistance.

References

- 1 Lane GA, Nahrwold ML, Tait AR, Taylor-Busch M, Cohen PJ. Anesthetics as teratogens: nitrous oxide is fetotoxic, xenon is not. Science 1980; 210: 899–901.
- 2 Lachmann B, Armbruster S, Schairer W, et al. Safety and efficacy of xenon in routine use as an inhalational anaesthetic. Lancet 1990; 335: 1413–5.
- 3 Boomsma F, Rupreht J, Man in't Veld AJ, de Jong FH, Dzoljic M, Lachmann B. Haemodynamic and neurohumoral effects of xenon anaesthesia. A comparison with nitrous oxide. Anaesthesia 1990; 45: 273–8.
- 4 *Giunta F, Natale G, Del Turco M, Del Tacca M.* Xenon: a review of its anaesthetic and pharmacological properties. Appl Cardiopul Pathophysiol 1996; 6: 95–103.
- 5 Goto T, Saito H, Shinkai M, Nakata Y, Ichinose F, Morita S. Xenon provides faster emergence from anesthesia than does nitrous oxide-sevoflurane or nitrous oxide-isoflurane. Anesthesiology 1997; 86: 1273–8.
- 6 Steward A, Allott PR, Cowles AL, Mapleson WW. Solubility coefficients for inhaled anaesthetics for water, oil and biological media. Br J Anaesth 1973; 45: 282–93.
- 7 Goto T, Suwa K, Uezono S, Ichinose F, Uchiyama M, Morita S. The blood–gas partition coefficient of xenon may be lower than generally accepted. Br J Anaesth 1998; 80: 255–6.
- 8 Cullen SC, Eger EI II, Cullen BF, Gregory P. Observations on the anesthetic effect of the combination of xenon and halothane. Anesthesiology 1969; 31: 305–9.
- 9 Kennedy RR, Stokes JW, Downing P. Anaesthesia and the 'inert' gases with special reference to xenon. Anaesth Intensive Care 1992; 20: 66–70.
- 10 Mazoit JX, Orhant EE, Boïco O, Kantelip J-P, Samii K. Myocardial uptake of bupivacaine: I. Pharmacokinetics and pharmacodynamics of lidocaine and bupivacaine in the isolated perfused rabbit heart. Anesth Analg 1993; 77: 469–76.
- 11 Stowe DF, Monroe SM, Marijic J, Rooney RT, Bosnjak ZJ, Kampine JP. Effects of nitrous oxide on contractile function and metabolism of the isolated heart. Anesthesiology 1990; 73: 1220–6.

- 12 Marx T, Froeba G, Wagner D, Baeder S, Goertz A, Georgieff M. Effects on haemodynamics and catecholamine release of xenon anaesthesia compared with total i.v. anaesthesia in the pig. Br J Anaesth 1997; 78: 326–7.
- 13 Hettrick DA, Pagel PS, Kersten JR, et al. Cardiovascular effects of xenon in isoflurane-anesthetized dogs with dilated cardiomyopathy. Anesthesiology 1998; 89: 1166–73.
- 14 Rehmert GC, Kwok WM, Stadnicka A, Weigt HU, Georgrieff M, Bosnjak ZJ. Xenon does not inhibit cardiac ion channels. Anesthesiology 1998; 89: A594 (abstract).
- 15 Kamibayashi T, Hayashi Y, Mammoto T, et al. Comparison of myocardial epinephrine sensitization during xenon, halothane and nitrous oxide anesthesia in dogs. Anesthesiology 1998; 89: A614 (abstract).
- 16 Morita S, Goto T, Niimi Y, Ichinose F, Saito H. Xenon produces minimal cardiac depression in patients under fentanyl-midazolam anesthesia. Anesthesiology 1996; 85 A362 (abstract).
- 17 Stowe DF, Rehmert GC, Kwok W-M, Weigt HU, Georgieff M, Bosnjak ZJ. Xenon does not alter cardiac function or major cation currents in isolated guinea pig hearts or myocytes. Anesthesiology 2000; 92: 516–22.
- 18 Luttropp HH, Romner B, Perhag L, Eskilsson J, Fredriksen S, Werner O. Left ventricular performance and cerebral haemodynamics during xenon anaesthesia. A transoesophageal echocardiography and transcranial Doppler sonography study. Anaesthesia 1993; 48: 1045–9.
- 19 Goto T, Matsukawa T, Sessler DI, et al. Thermoregulatory thresholds for vasoconstriction in patients anesthetized with various 1-minimum alveolar concentration combinations of xenon, nitrous oxide, and isoflurane. Anesthesiology 1999; 91: 626–32.
- 20 Ishiguro Y, Goto T, Nakata Y, Terui K, Niimi Y, Morita S. Effect of xenon on autonomic cardiovascular control—comparison with isoflurane and nitrous oxide. J Clin Anesth 2000; 12: 196–201.
- 21 Bootsma M, Swenne CA, Van Bolhuis HH, Chang PC, Cats VM, Bruschke AVG. Heart rate and heart rate variability as indexes of sympathovagal balance. Am J Physiol 1994; 266: H1565–71.
- 22 Kawamura R, Stanley TH, English JB, Hill GE, Liu W-S, Webster LR. Cardiovascular responses to nitrous oxide exposure for two hours in man. Anesth Analg 1980; 59: 93–9.
- 23 Eisele JH, Smith NT. Cardiovascular effects of 40 percent nitrous oxide in man. Anesth Analg 1972; 51: 956–63.
- 24 Lichtenthal P, Philip J, Sloss LJ, Gabel R, Lesch M. Administration of nitrous oxide in normal subjects. Evaluation of systems of gas delivery for their clinical

use and hemodynamic effects. Chest 1977; 72: 316–22.

- 25 Carton EG, Wanek LA, Housmans PR. Effects of nitrous oxide on contractility, relaxation and the intracellular calcium transient of isolated mammalian ventricular myocardium. J Pharmacol Exp Ther 1991; 257: 843–9.
- 26 Price HL. Myocardial depression by nitrous oxide and its reversal by Ca⁺⁺. Anesthesiology 1976; 44: 211–5.
- 27 Lawson D, Frazer MJ, Lynch III C. Nitrous oxide effects on isolated myocardium: a reexamination in vitro. Anesthesiology 1990; 73: 930–43.
- 28 Sellgren J, Pontén J, Wallin BG. Percutaneous recording of muscle nerve sympathetic activity during propofol, nitrous oxide, and isoflurane anesthesia in humans. Anesthesiology 1990; 73: 20–7.
- 29 Ebert TJ, Kampine JP. Nitrous oxide augments sympathetic outflow: direct evidence from human peroneal nerve recordings. Anesth Analg 1989; 69: 444–9.
- 30 Lynch III C, Baum J, Tenbrinck R. Xenon anesthesia. Anesthesiology 2000; 92: 865–70.